London-listed AstraZeneca said on Monday it would pay $1 billion upfront to Daiichi in staggered payments for an experimental drug called DS-1062, which belongs to a promising class of therapies called antibody drug conjugates (ADC). AstraZeneca has been bolstering its portfolio of cancer therapies, particularly ADCs, a major area of focus for the company as it also ploughs on with its coronavirus vaccine candidate. “We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2,” AstraZeneca Chief Executive Pascal Soriot said, referring to a protein found on some cancer cell surfaces.
from Yahoo Finance https://ift.tt/303kJcE
Leave a Reply